secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXAGEN INC. (XGN)
CIK:        0001274737
Form:       8-K
Filed at:   2025-03-11T23:59:59+00:00
Accession:  0001274737-25-000018
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Exagen reports record FY 2024 revenue of $55.6M; guides Q1 2025 revenue ≥$14.5M
-------------------------------------------------------------------------------

- Q4 2024 revenue $13.655M; gross margin 62.1%; FY revenue $55.641M, up from prior year.
- AVISE CTD trailing 12-mo ASP reached $411, a $75 increase per test.
- FY net loss improved ~$8M YoY to ($15.1M); adjusted EBITDA loss improved ~$7M to ($10.1M).
- Surpassed 1 million patients tested with AVISE CTD; launched new SLE and RA biomarker assays in Jan 2025.
- Expects positive adjusted EBITDA in Q4 2025; Q1 2025 revenue at least $14.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1274737/000127473725000018/0001274737-25-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1274737/000127473725000018/exdx-20250311.htm
  HTML page:      https://secwatch.observer/filing/0001274737-25-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer